6 completed, 5 active not recruiting, 3 recruiting, 2 not yet recruiting. 10 Phase 1, 5 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 6, Active not recruiting 3, Recruiting 1 |
| Phase 2 | 5 | Recruiting 3, Not yet recruiting 2 |
| Phase 3 | 2 | Active not recruiting 2 |
Follow Imlunestrant: new trials by email Literature Review of Imlunestrant trials Research Report on Imlunestrant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial Imlunestrant, Abemaciclib, Selinexor - Low Grade Ovarian Serous Adenocarcinoma, Endometrial Cancer | Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 60 | 2026-12-01 | 2026-09-21 |
| Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer Imlunestrant + abemaciclib, (dd)EC*4-T*4 - Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 189 | 2026-07-01 | 2026-02-18 |
| Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial Abemaciclib, Biospecimen Collection, Imlunestrant - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 42 | 2026-05-18 | 2026-08-20 |
| A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer Imlunestrant, Goserelin, Tamoxifen 20 mg - Breast Neoplasms | Phase 2 | Recruiting | Eli Lilly and Company | 600 | 2026-05-13 | 2026-10-08 |
| First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors STX-478, Fulvestrant, Ribociclib - Breast Cancer, Solid Tumors, Adult | Phase 1 / Phase 2 | Recruiting | Eli Lilly and Company | 880 | 2023-04-17 | 2026-07-07 |
| A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer LY3484356 - Breast Neoplasms | Phase 1 | Active not recruiting | Eli Lilly and Company | 17 | 2022-10-09 | 2026-04-13 |
| A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer Imlunestrant, Tamoxifen, Anastrozole - Breast Neoplasms | Phase 3 | Active not recruiting | Eli Lilly and Company | 8000 | 2022-10-04 | 2026-04-02 |
| A Study of Imlunestrant (LY3484356) in Healthy Women Midazolam, Imlunestrant - Healthy | Phase 1 | Completed | Eli Lilly and Company | 20 | 2022-09-12 | 2025-11-12 |
| A Study of Imlunestrant (LY3484356) in Female Healthy Participants Imlunestrant, Repaglinide, Omeprazole - Healthy | Phase 1 | Completed | Eli Lilly and Company | 113 | 2022-07-07 | 2025-12-12 |
| A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function Imlunestrant - Hepatic Insufficiency, Healthy | Phase 1 | Completed | Eli Lilly and Company | 27 | 2022-07-05 | 2025-11-12 |
| A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors LOXO-783, Fulvestrant, Imlunestrant - Breast Cancer | Phase 1 | Active not recruiting | Eli Lilly and Company | 260 | 2022-05-11 | 2026-10-14 |
| A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer Imlunestrant, Exemestane, Fulvestrant - Breast Neoplasms, Neoplasm Metastasis | Phase 3 | Active not recruiting | Eli Lilly and Company | 874 | 2021-10-04 | 2026-07-22 |
| A Study of [¹⁴C]-LY3484356 in Healthy Female Participants [¹⁴C]-LY3484356, LY3484356, [¹⁴C]-LY3484356 (IV) - Healthy | Phase 1 | Completed | Eli Lilly and Company | 16 | 2021-08-13 | 2025-12-05 |
| A Study of LY3484356 in Healthy Female Participants LY3484356, Omeprazole, Itraconazole - Healthy | Phase 1 | Completed | Eli Lilly and Company | 82 | 2021-04-26 | 2025-12-11 |
| A Study of LY3484356 in Women With Breast Cancer Before Having Surgery LY3484356 - Breast Cancer | Phase 1 | Completed | Eli Lilly and Company | 87 | 2021-04-21 | 2025-11-12 |
| A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer LY3484356, Abemaciclib, Everolimus - Breast Cancer, Advanced Breast Cancer | Phase 1 | Active not recruiting | Eli Lilly and Company | 379 | 2019-12-10 | 2026-06-22 |
Breast Neoplasms (9) · Endometrial Neoplasms (3) · Ovarian Neoplasms (2) · Breast Diseases (1) · Head and Neck Neoplasms (1) · Hepatic Insufficiency (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Neoplasms by Site (1) · Squamous Cell Carcinoma of Head and Neck (1) · Uterine Cervical Neoplasms (1)
Eli Lilly and Company (13) · Dana-Farber Cancer Institute (1) · Fudan University (1) · Jonsson Comprehensive Cancer Center (1)
United States (13) · Belgium (7) · France (7) · Germany (6) · Spain (6) · China (5) · Japan (5) · Australia (4) · Italy (4) · South Korea (4) · Taiwan (4) · Ireland (3) · Netherlands (3) · United Kingdom (3) · Argentina (2)
Marla Lipsyc-Sharf (1) · Panagiotis Konstantinopoulos, MD, PhD (1)
PMID 39241211, PMID 39660834, PMID 41423595
2023 (2), 2019 (1), 2025 (1)